Ruhi Ahmed, Ph.D., RAC
Senior Director, Program Development
Ultragenyx Pharmaceutical Inc.
Dr. Ahmed’s experience and background includes over 10 years in the pharmaceutical and biotechnology industry, specifically focused on regulatory drug development and life cycle management of programs from the preclinical to the commercial stage. Dr. Ahmed joined Ultragenyx as a Senior Director in both the Regulatory Affairs and the Program Development Teams in August 2011. Prior to joining Ultragenyx, Dr. Ahmed worked in positions of increasing responsibility in the Regulatory Affairs Department at BioMarin Pharmaceutical Inc. and at Actavis Inc. (formerly known as Watson Pharmaceuticals Inc).
Dr. Ahmed received her B.A. in Biology and an M.A. in Biochemistry from The University of Texas at Austin; an M.Sc. in Regulatory Sciences and a Ph.D. in Molecular Pharmacology and Toxicology from the University of Southern California, Los Angeles. She is currently also serving as a member of the Parenteral Drug Association’s (PDA) Regulatory Affairs and Quality Advisory Board.